Global Cooperation on Antibody-Drug Conjugates: Key Driver of Progress in HER2-Dependent Metastatic Breast Cancer Treatment
An assessment of progress with antibody-drug conjugates (ADCs) for the treatment of HER2-dependent metastatic breast cancer was given at the 2024 Chinese Society of Clinical Oncology (CSCO) Annual Meeting. The President-Elect of the European Society for Medical Oncology (ESMO), Giuseppe Curigliano, MD, PhD, Director of the Early Drug Development for Innovative Therapies Division at the European Institute of Oncology and the University of Milano in Italy, told Oncology Times reporter Peter Goodwin about the broadening scope of ADCs in breast cancer and his reasons for encouraging ESMO and CSCO to continue to expand their co-operation.
--------
8:43
--------
8:43
World-Wide Clinical Perspectives from Chinese Society of Clinical Oncology’s Globally Upscale 2024 Annual Meeting
At the opening session of the Chinese Society of Clinical Oncology (CSCO) 2024 Annual Meeting, attended by nearly 30,000 cancer specialists, Oncology Times reporter Peter Goodwin asked the President of CSCO, Xu Ruihua, MD, PhD, Professor and President of Sun Yat-sen University Cancer Center in Guangzhou, China, to talk about some of the ways that progress in cancer treatments had been made more productive by co-operation between Chinese and Western centers of oncology excellence.
--------
8:21
--------
8:21
Unintentional Bias of Breast Cancer Randomized Clinical Trial Interpretations Through Discontinuation Imbalance
Some of the big randomized clinical trials could lead to unintentional bias because of an imbalance of assigned treatment discontinuations between experimental and control arms, according to ASCO poster author Faris Tamimi, MD, at the University Health Network Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre. OncTimesTalk correspondent Peter Goodwin talked with Tamimi at the 2023 ASCO Annual Meeting.
--------
11:54
--------
11:54
Straight Talk with Dr. Brian Bolwell: Letting it Go
Oncology Times sits down with Brian J. Bolwell, MD, the Chairman of the Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic Lerner School of Medicine. In his recurring Oncology Times column Straight Talk: Today's Cancer Centers, Dr. Bolwell dispenses wisdom on how to be a better leader. In this episode, Dr. Bolwell discusses the art of forgiveness; including how to let it go when there is conflict and breach of trust.
--------
12:46
--------
12:46
Colleague Conversations: A Look at Germline Predisposition to Hematologic Malignancies
Colleague Conversations offers insights into hematology/oncology from two different perspectives: a seasoned hematologist/oncologist and a clinician earlier in their career. Oncology Times reporter Catlin Nalley sat down with Lucy A. Godley, MD, PhD, and Gina Keiffer, MD, to discuss germline predisposition to hematologic malignancies. They delve into our growing understanding of this area, including current and future research endeavors, and examine how germline predisposition intersects with disparities in cancer care. Godley is the Hospira Foundation Professor of Medicine and Human Genetics at The University of Chicago Medicine, and Keiffer is board certified in Internal Medicine, Hematology, and Oncology at Jefferson Health in New Jersey.
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care professionals. Learn more about our award-winning journal!
New Zealand